JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lubberink, M.
Right arrow Articles by Westlin, J.-E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lubberink, M.
Right arrow Articles by Westlin, J.-E.
Journal of Nuclear Medicine Vol. 43 No. 10 1391-1397
© 2002 by Society of Nuclear Medicine

Basic Science Investigations

110mIn-DTPA-D-Phe1-Octreotide for Imaging of Neuroendocrine Tumors with PET

Mark Lubberink, PhD1,2, Vladimir Tolmachev, PhD1, Charles Widström, MSc2, Alexander Bruskin, PhD3, Hans Lundqvist, PhD1 and Jan-Erik Westlin, PhD, MD1

1 Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
2 Department of Hospital Physics, Uppsala University Hospital, Uppsala, Sweden
3 Institute of Theoretical and Experimental Physics, Moscow, Russia

The somatostatin analog diethylenetriaminepentaacetic acid (DTPA)-D-Phe1-octreotide labeled with 111In has been applied extensively for diagnosis of neuroendocrine tumors using SPECT or planar scintigraphy. However, the spatial resolution of planar scintigraphy and SPECT prohibits imaging of small tumors, and the quantification accuracy of both methods is limited. Methods: We developed a method to prepare the positron-emitting radiopharmaceutical 110mIn-DTPA-D-Phe1-octreotide based on a commercially available kit. Phantom studies were done to investigate and compare the performance of 110mIn PET and 111In SPECT. A clinical imaging study using 110mIn-DTPA-D-Phe1-octreotide and PET was done to investigate the application of this radiopharmaceutical. Results: An almost 3-fold better resolution and much better quantitative capabilities were found for 110mIn PET than for 111In SPECT. The clinical imaging study demonstrated the potential use of 110mIn-octreotide in PET to image tumors and quantify radioactivity uptake in humans using 110mIn-DTPA-D-Phe1-octreotide. Conclusion: PET with 110mIn-DTPA-D-Phe1-octreotide greatly improved detection of small tumors and offers a possibility of more accurate quantification of tumor uptake than can be obtained with 111In-DTPA-D-Phe1-octreotide and SPECT.

Key Words: PET • SPECT • 110mIn • 111mIn • octreotide






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2002 by the Society of Nuclear Medicine.